Neuroblastoma
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | DIS-NEUROBLASTOMA |
|---|---|
| Tipo | Doença |
| Alegais | Tumor neuroblástico periférico pediátricoTumor embrional do sistema nervoso simpáticoНейробластома |
| Estado | reviewed 2026-05-20 | pending_clinical_signoff |
| Doenças | Nenhuma declaração |
| Fontes | SRC-NCCN-PEDIATRIC-SARCOMA |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9500/3 |
|---|---|
| icd_o_3_topography | ["C74.9", "C47", "C48"] |
| icd_10 | C74.9 |
| who_classification | WHO Endocrine Tumours 5th ed (2022): Neuroblastoma — peripheral neuroblastic tumor of sympathetic-nervous-system origin; INSS + INRG staging; MYCN amplification + ALK alterations are key prognostic + targetable |
Notas
COG + SIOPEN risk-stratified treatment frameworks. Anti-GD2 immuno- therapy (dinutuximab + cytokines) is high-risk standard since 2009; ch14.18/Naxitamab as alternative. Lorlatinib + crizotinib for ALK- mutant subset (cooperative-group trials). MIBG-iodine131 + lutathera therapy for MIBG-avid relapsed disease. Surveillance for syndromic predisposition carriers: abdominal US + urinary catecholamines q3-6mo to age 8 in Costello + Beckwith-Wiedemann.
Usado por
Não há referências reversas encontradas no corpus YAML.